The current price of AKTS is $15.82 — it has increased by 6.53% since the previous close. Data as of Nov 6, 2026.
AKTS is down 1.19% over the past week, down 12.11% over the past month and down 29.37% over the past year. The price is below its 200-day moving average of $20.92.
Analysts' average 12-month price target for AKTS is $37.40, which implies 136.41% upside from the current price. Individual estimates range from $35.00 to $40.00.
Of the 10 analysts covering Aktis Oncology, Inc., 1 rates it a strong buy and 9 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Aktis Oncology, Inc. has a market capitalization of $850.27M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Aktis Oncology, Inc. posted a loss of $0.44 per share against an estimate of -$0.4307, missing expectations by 2.17%. Upcoming reports are listed in the earnings calendar.
Aktis Oncology, Inc. reported revenue of $3.38M in its most recent quarter. Analysts had expected $2.63M.
Aktis Oncology, Inc. has not paid any dividends over the past year.
In the latest trading session AKTS moved between $14.83 and $15.97, a range of 7.21% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Aktis Oncology, Inc. shows a sell rating today and a sell rating on the weekly timeframe. Technical ratings are indicators, not investment advice.
Over the past 52 weeks AKTS has traded between $13.96 and $34.19. The current price is 53.73% below its 52-week high.
Figures as of Nov 6, 2026. This information is provided for general purposes only and is not investment advice.